# Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery

> **NCT00057798** · PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 21 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **DRUG:** vinorelbine ditartrate
- **GENETIC:** cytogenetic analysis
- **GENETIC:** loss of heterozygosity analysis
- **GENETIC:** microarray analysis
- **PROCEDURE:** conventional surgery
- **PROCEDURE:** neoadjuvant therapy

## Key facts

- **NCT ID:** NCT00057798
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-03
- **Primary completion:** 2003-05
- **Final completion:** 2008-06
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2011-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00057798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00057798, "Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00057798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*